Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Halo Collective Inc. (HCANF)
Toronto, ON, CA
Founded in 2016 and headquartered in Toronto, Canada, Halo Collective Inc. is a vertically integrated cannabis company. (The firm adopted its current name in January 2021, previously operating as Halo Labs Inc.) Its core operations involve cultivating, manufacturing, and distributing cannabis products throughout the United States. The company specializes in growing, extracting, and processing various forms of cannabis, including flowers, oils, and concentrates. Beyond these, Halo Collective also offers a range of edible products, such as cannabis-infused gummies and a distinctive syrup beverage, available in California and Oregon. Halo Collective markets both its own branded products—like Hush, Mojave, and Exhale—and private label items, primarily selling its cannabis offerings to dispensaries. Its clientele includes licensed retailers and wholesalers. The company also maintains significant collaborations, including a strategic partnership with High Tide Inc. and an alliance with OG DNA Genetics Inc. focused on developing cannabis genetics in Oregon.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | -99.40% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-32.2% Q2'23: -48.0% (vs Q2'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+87.4% ★ Q2'23: +99.4% (vs Q2'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-294.7% Q2'23: -13.1% (vs Q2'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-315.2% Q2'23: -182.1% (vs Q2'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-167.8% Q2'23: -74.4% (vs Q2'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+591.8% Q2'23: +10,695.3% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.24× Q2'23: -0.69× (vs Q2'22)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
28.15M
est: 44.12M (-36.2%)
|
21.64M
est: 25.86M (-16.3%)
|
36.18M
est: 40.12M (-9.8%)
|
24.54M
est: 67.19M (-63.5%)
|
44.12M
est.
|
44.12M
44.12M – 44.12M
+0.0% YoY
|
25.86M
25.86M – 25.86M
-41.4% YoY
|
40.12M
40.12M – 40.12M
+55.1% YoY
|
67.19M
67.19M – 67.19M
+67.5% YoY
|
| EBITDA |
-24.61M
est: -43.01M (+42.8%)
|
-38.16M
est: -25.21M (-51.3%)
|
-37.70M
est: -39.11M (+3.6%)
|
-73.85M
est: -65.50M (-12.8%)
|
-43.01M
est.
|
-43.01M
-43.01M – -43.01M
+0.0% YoY
|
-25.21M
-25.21M – -25.21M
+41.4% YoY
|
-39.11M
-39.11M – -39.11M
-55.1% YoY
|
-65.50M
-65.50M – -65.50M
-67.5% YoY
|
| EBIT |
-26.00M
est: -43.53M (+40.3%)
|
-40.56M
est: -25.52M (-58.9%)
|
-40.25M
est: -39.59M (-1.7%)
|
-77.34M
est: -66.29M (-16.7%)
|
-43.53M
est.
|
-43.53M
-43.53M – -43.53M
+0.0% YoY
|
-25.52M
-25.52M – -25.52M
+41.4% YoY
|
-39.59M
-39.59M – -39.59M
-55.1% YoY
|
-66.29M
-66.29M – -66.29M
-67.5% YoY
|
| Net Income |
-27.62M
|
-41.18M
est: -788.88M (+94.8%)
|
-94.61M
est: -946.03M (+90.0%)
|
-83.87M
est: -698.83M (+88.0%)
|
—
est.
|
-788.88M
-788.88M – -788.88M
|
-788.88M
-788.88M – -788.88M
+0.0% YoY
|
-946.03M
-946.03M – -946.03M
-19.9% YoY
|
-698.83M
-698.83M – -698.83M
+26.1% YoY
|
| SGA |
25.69M
est: 49.07M (-47.6%)
|
23.20M
est: 28.77M (-19.4%)
|
43.19M
est: 44.63M (-3.2%)
|
36.65M
est: 74.73M (-51.0%)
|
49.07M
est.
|
49.07M
49.07M – 49.07M
+0.0% YoY
|
28.77M
28.77M – 28.77M
-41.4% YoY
|
44.63M
44.63M – 44.63M
+55.1% YoY
|
74.73M
74.73M – 74.73M
+67.5% YoY
|
| EPS |
-1,400.00
|
-727.00
est: -99.24 (-632.5%)
|
-83.62
est: -119.01 (+29.7%)
|
-10.55
est: -87.91 (+88.0%)
|
—
est.
|
-99.24
-99.24 – -99.24
|
-99.24
-99.24 – -99.24
+0.0% YoY
|
-119.01
-119.01 – -119.01
-19.9% YoY
|
-87.91
-87.91 – -87.91
+26.1% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard Dustin Jessup | Chief Revenue Officer | 343.4K | male |
| Marshall Minor | Interim Chief Financial Officer & Senior Vice President of Finance | 287.3K | male |
| Beau McKeon | Senior Vice President of Retail | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HCANF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
